Sharemaestro Newsreel

Earnings To Watch: RxSight Inc (RXST) Q2 2026 -- GF Value Sees 519% Upside

RxSight Inc (NASDAQ:RXST) is scheduled to release its Q2 2026 earnings on August 7, 2026, with revenue expected at $32.55 million and earnings at $-0.32 per share. GuruFocus estimates a significant upside of 518.60% for RXST based on its GF Value of $38.91, despite …

Artivion, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:AORT) 2026-08-07

Artivion, Inc. (AORT) released its 2026 Q2 earnings call presentation. The company reported an EPS of $0.13, beating estimates by $0.03, and revenue of $125.76 million, an 11.32% year-over-year increase, beating estimates by $5.74 million. This article provides access to the slide deck published …

CVRx (NASDAQ:CVRX) Announces Quarterly Earnings Results

Zimmer Biomet Holdings (ZBH) Following Its Beat And Guidance Lift, Is The Valuation Catching Up?

Zimmer Biomet Holdings (ZBH) recently reported stronger-than-expected quarterly results and increased its guidance, driven by solid execution in U.S. hip and technology lines and sales force restructuring progress. Despite a significant 5-year decline in shareholder return, the company's recent 90-day share price return of …

AVITA Medical Inc (AVHHL) (Q2 2026) Earnings Call Highlights: Revenue Surges 18% to $21. ...

AVITA Medical (AVHHL) reported strong Q2 2026 results with revenue up 18% year-over-year to $21.7 million, exceeding $20 million for the first time. The company raised its full-year 2026 revenue guidance and anticipates achieving cash flow breakeven by Q4 2026. While operating and net …

LENSAR to report Q2 2026 results, host conference call

LENSAR will release its second-quarter 2026 financial results before market open on August 13, 2026. The company's management will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. The webcast will be accessible via LENSAR's …

Apyx Medical Corp (APYX) (Q2 2026) Earnings Call Highlights: Revenue Surges 22% on Power Lipo ...

Apyx Medical Corp (APYX) reported a 22% increase in Q2 2026 revenue, reaching $13.9 million, primarily driven by a 28% surge in surgical aesthetics product sales and expanded FDA clearance for power liposuction on its Aion platform. Despite a net loss of $3.2 million, …

TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ...

TriSalus Life Sciences Inc (TLSI) announced a new CMS G-code for TriNav reimbursement in office-based labs, significantly expanding market access and supporting full-year 2026 revenue guidance of $54 million to $57 million. While gross margin improved to 86.8%, Q2 revenue growth was modest at …

Profound Medical Corp (PROF) (Q2 2026) Earnings Call Highlights: Record Orders and ...

Profound Medical Corp (NASDAQ:PROF) reported strong Q2 2026 performance with revenue growth and improved gross margins, despite a $3.1 million revenue recognition timing issue. The company saw accelerating commercial momentum, record orders, and expanding payer coverage for its Tulsa procedure, supported by positive clinical …

iRhythm Holdings Inc (IRTC) (Q2 2026) Earnings Call Highlights: Record Profitability and ...

This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points iRhythm Holdings Inc (NASDAQ:IRTC) delivered its seventh consecutive quarter of revenue growth above 20%, with …

Inogen Inc (INGN) (Q2 2026) Earnings Call Highlights: Strong International Growth and New ...

Inogen Inc. (INGN) reported strong international revenue growth of 15% year-over-year and core POC unit volume growth of over 12% in Q2 2026, with new products Voxy and Aurora gaining traction. Despite these positive indicators and an expanded gross margin, the company lowered its …

Enovis earnings beat by $0.05, revenue topped estimates

Enovis Q2 2026 presentation shows margin gains, stock falls 9%

AVITA Medical Shares Climb 16.41% as ASX:AVH Approaches a Key 2026 Earnings Checkpoint

Enovis Q2 2026 slides show margin gains despite stock decline

Enovis Corporation reported strong second-quarter 2026 results, showing 5% organic growth, significant margin expansion, and improved free cash flow. Despite beating earnings expectations and reaffirming full-year guidance, the stock declined 8.4%, reflecting investor concerns about near-term headwinds and the absence of raised guidance. The …

Beyond Air regains Nasdaq compliance after reverse stock split By Investing.com

Beyond Air (NASDAQ:XAIR) has regained compliance with Nasdaq's minimum bid price requirement following a 1-for-20 reverse stock split. The company previously received a delisting notice and was granted conditional continued listing. Despite its stock being down significantly over the past year, Beyond Air recently …

Narrower Losses And Reaffirmed 2026 Revenue Guidance Might Change The Case For Investing In Alphatec Holdings (ATEC)

Alphatec Holdings, Inc. recently reported past second-quarter 2026 results showing its net loss narrowed to US$25.78 million, or US$0.16 per share, and reaffirmed full-year 2026 revenue guidance of about US$882 million, including US$805 million of surgical revenue and US$77 million of EOS revenue. Alongside …

Earnings call transcript: Cytosorbents posts modest Q2 2026 revenue beat

Cytosorbents reported a modest revenue beat in Q2 2026, with revenue of $9.6 million slightly exceeding Wall Street expectations. The company demonstrated operational improvements, including increased gross margins, reduced operating expenses, and a significant decrease in operating cash burn, aiming for breakeven in H2 …

CytoSorbents (NASDAQ: CTSO) Q2 loss, higher margins and four value drivers

CytoSorbents reported a Q2 2026 net loss of $4.417 million, compared to a net income of $1.947 million a year prior, despite product gross margin improving to 73%. The company highlighted significant improvements in Adjusted EBITDA loss and operating cash burn, attributing them to …

Outset Medical earnings missed by $0.05, revenue topped estimates

Inogen, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:INGN) 2026-08-06

Haemonetics (NYSE: HAE) grows revenue 5.6% in Q1 2027

Haemonetics Corporation (NYSE: HAE) reported a 5.6% increase in net revenues for Q1 fiscal 2027, reaching $339.38 million. Operating income grew by 6.7% to $57.46 million, while diluted EPS rose 2.9% to $0.72. The company also detailed its segment reorganization into Apheresis and MedSurg, …

Enovis reaffirms 2026 outlook and targets >25% free cash flow conversion as Arvis rollout expands

Earnings Call Insights: Enovis (ENOV) Q2 2026 MANAGEMENT VIEW * CEO Damien McDonald said Q2 results showed “the strength and stability of our diversified product portfolio” and reported “organic growth of 5%, driven by 6% organic growth in Recon and 3% organic growth in …

Zimmer Biomet (ZBH) Stock Gets Fair Value Bump After Mixed Analyst Views

Zimmer Biomet Holdings (ZBH) has seen its fair value updated by analysts, with some taking a bullish stance due to undervaluation and growth opportunities, while others remain cautious, emphasizing consistent execution and margin stabilization. The company's fair value moved from US$98.70 to approximately US$102.19, …

Globus Medical (NYSE: GMED) lifts 2026 EPS outlook on strong Q2 performance

Globus Medical (NYSE: GMED) announced strong second-quarter 2026 results, with worldwide net sales increasing by 5.9% to $789.6 million and non-GAAP diluted EPS rising 55.8% to $1.34. The company reaffirmed its 2026 revenue guidance of $3.18–$3.22 billion but raised its non-GAAP fully diluted EPS …

Earnings call transcript: AVITA Medical tops Q2 2026 estimates, shares jump

AVITA Medical (RCEL) exceeded Q2 2026 earnings estimates, reporting a narrower loss of $0.25 per share and revenue of $21.7 million, surpassing forecasts. The company raised its full-year 2026 revenue guidance to $86 million-$89 million and expects to achieve cash flow breakeven and generate …

Hyperfine Q2 Earnings Call Highlights

Key Points Interested in Hyperfine, Inc.? Here are five stocks we like better. Revenue and system sales accelerated: Second-quarter revenue rose 45% year over year to $3.9 million, with 12 systems sold versus eight a year earlier. First-half revenue increased 62% to $7.8 million, …

Earnings call transcript: Hyperfine’s Q2 2026 revenue rises 45% but misses estimates

Bio-Rad Laboratories, Inc. $BIO Shares Bought by California State Teachers Retirement System

The California State Teachers Retirement System increased its stake in Bio-Rad Laboratories (NYSE:BIO) by 22.9% in the first quarter, now owning 21,932 shares worth $6.1 million. Bio-Rad Laboratories recently reported strong Q2 adjusted earnings of $2.62 per share, exceeding analyst estimates, although revenue was …

Sanuwave Health Reports Q2 2026 Financial Results, Withdraws Full-Year Guidance on Medicare Reimbursement Uncertainty

Sanuwave Health reported Q2 2026 revenues of $9.7 million, a 3% decline from Q2 2025, resulting in a net loss of $0.7 million. The company has withdrawn its fiscal year 2026 guidance due to uncertainties surrounding Medicare reimbursement changes, particularly the proposed rule for …

CVRx Q2 Earnings Call Highlights

CVRx Inc (CVRX) reported Q2 2026 revenue of $15.7 million, up 16% year-over-year, with an 87% gross margin. However, the company lowered its full-year 2026 revenue guidance due to sales execution issues, including high sales force turnover and challenges with a major Medicare Advantage …

Alphatec Holdings, Inc. $ATEC Shares Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC significantly increased its stake in Alphatec Holdings, Inc. ($ATEC) by 21.3% in the first quarter of 2026, acquiring an additional 184,969 shares and bringing its total holdings to over 1 million shares. Other institutional investors also boosted their positions in the …

Earnings call transcript: TriSalus tops Q2 revenue forecast, stock slips after hours

TriSalus Life Sciences reported Q2 revenue of $11.4 million, surpassing forecasts, driven by increased adoption of its TriNav system. Despite the revenue beat, the stock slipped after hours due to a wider adjusted EBITDA loss and higher sales and marketing expenses. The company reiterated …

Is Artivion Inc (AORT) Undervalued Despite $125.8 Million Revenue in Q2? GF Score: 82/100

Artivion Inc (AORT) reported Q2 2026 revenues of $125.8 million, an 11% year-over-year increase, exceeding analyst estimates, yet posted a net loss of $13.5 million. Despite the loss, driven partly by foreign currency revaluation and increased operating expenses, the company strengthened its product portfolio …

Is Tandem Diabetes Care Inc (TNDM) a Value Opportunity After Q2 Earnings Miss? GF Score: 66/100

Cytosorbents Corp 2Q 2026: Revenue $9.63M, EPS ($0.07) — 10-Q Summary

Cytosorbents Corp reported its second-quarter 2026 financial results, with revenue holding steady year-over-year at $9.63 million but posting a loss per share of ($0.07), a decline from the prior year's profit. The company is focusing on strategic initiatives such as channel shifts, cost reductions, …